Back to Search Start Over

Applications of Genome-Editing Technologies for Type 1 Diabetes

Authors :
Rana El Nahas
Mohammad Ameen Al-Aghbar
Laura Herrero
Nicholas van Panhuys
Meritxell Espino-Guarch
Source :
International Journal of Molecular Sciences, Vol 25, Iss 1, p 344 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells by the immune system. Although conventional therapeutic modalities, such as insulin injection, remain a mainstay, recent years have witnessed the emergence of novel treatment approaches encompassing immunomodulatory therapies, such as stem cell and β-cell transplantation, along with revolutionary gene-editing techniques. Notably, recent research endeavors have enabled the reshaping of the T-cell repertoire, leading to the prevention of T1D development. Furthermore, CRISPR–Cas9 technology has demonstrated remarkable potential in targeting endogenous gene activation, ushering in a promising avenue for the precise guidance of mesenchymal stem cells (MSCs) toward differentiation into insulin-producing cells. This innovative approach holds substantial promise for the treatment of T1D. In this review, we focus on studies that have developed T1D models and treatments using gene-editing systems.

Details

Language :
English
ISSN :
25010344, 14220067, and 16616596
Volume :
25
Issue :
1
Database :
Directory of Open Access Journals
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
edsdoj.3591fbd996b04151903ed901ae3253b6
Document Type :
article
Full Text :
https://doi.org/10.3390/ijms25010344